STOCK TITAN
  1. Home
  2. NNBXF

Nanobiotix Labege (NNBXF) Stock Price, News & Analysis

NNBXF OTC
Published by Stock Titan Data refreshed

What Changed

Company Description

For FY2025, Nanobiotix Labege reported revenue of $38.3M with net income of -$28.1M and diluted earnings per share of -$0.59. The company operates at a net profit margin of -73.5%.

This page collects what Stock Titan holds for NNBXF, including price data, SEC filings, financial highlights, and short interest trends.

Stock Performance

Chart
—
-
-
-
Performance 1 year
-
Market Cap
-
Shares outstanding

NNBXF Metrics & Rankings

Revenue
$38.3M
#3,475
Piotroski F-Score
3/7 Partial
#5,125

Latest News

View All

No recent news available for NNBXF.

SEC Filings

View All

[6-K] CEO and CFO to present at Jefferies as Nanobiotix (NBTX) joins two London investor conferences.

[6-K] Four complete responses emerge in Nanobiotix (NBTX)'s 24-patient melanoma study.

[6-K] Nanobiotix (NBTX) had 54.7M votes eligible to be cast on Sept. 30, alongside 51M shares outstanding.

[6-K] After five years, finance chief Bart Van Rhijn will step down at Nanobiotix (NBTX).

[6-K] €110.9 million in cash, but a wider first-half loss for Nanobiotix (NBTX).

[6-K] Revenue fell from €26.6M to €5.6M, while Nanobiotix (NBTX) projects cash will fund operations into 2029.

[6-K] Nanobiotix (Nasdaq: NBTX) details August 2026 share and voting rights totals

[6-K] No dose-limiting toxicities in Nanobiotix (NBTX) lung cancer trial—how did patients fare at 1 year?

[6-K] Nanobiotix (NASDAQ: NBTX) to detail nanotech pipeline at H.C. Wainwright event

[6-K] Nanobiotix (NASDAQ: NBTX) updates share count and votes

Nanobiotix Labege has filed 10 recent SEC filings, including 10 Form 6-K. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all NNBXF SEC filings →

Financial Highlights

View Full Financials

Nanobiotix Labege generated $38.3M in revenue in FY2025, operating income reached -$12.7M (-33.2% operating margin), and net income was -$28.1M, reflecting a -73.5% net profit margin. Diluted earnings per share stood at -$0.59. The company generated -$39.2M in operating cash flow. The current ratio was 1.09, measuring current assets divided by current liabilities.

$38.3M
Revenue (FY2025)
-$28.1M
Net Income (FY2025)
-$0.59
Diluted EPS (FY2025)
-$39.2M
Operating Cash Flow
-73.5%
Net Profit Margin
-33.2%
Oper. Profit Margin

Upcoming Events

No upcoming events scheduled for NNBXF.

Short Interest History

Last 12 Months

Short interest in Nanobiotix Labege (NNBXF) currently stands at 119.9 thousand shares, up 11.5% from the previous reporting period, representing 0.3% of the float. Since May 2026, short interest has increased by 16548.6%.

Days to Cover History

Last 12 Months

Days to cover for Nanobiotix Labege (NNBXF) currently stands at 1000.0 days. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 9.8 to 1000.0 days.

Frequently Asked Questions

The FY2025 revenue of Nanobiotix Labege (NNBXF) is $38.3M, from its most recent completed fiscal year.

The FY2025 net income of Nanobiotix Labege (NNBXF) is -$28.1M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Nanobiotix Labege (NNBXF) is -$0.59 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Nanobiotix Labege (NNBXF) is -$39.2M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Nanobiotix Labege (NNBXF) is -73.5% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Nanobiotix Labege (NNBXF) is -33.2% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The current ratio of Nanobiotix Labege (NNBXF), current assets divided by current liabilities, was 1.09 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Nanobiotix Labege (NNBXF) is -$12.7M for FY2025, its most recent completed fiscal year. Learn about operating income.